A unique mentored educational opportunity for C1, C2 and ST3 (or equivalent)
Do you want to develop specialist skills in multiple sclerosis?
Research undertaken by Dr Riffat Tanveer has shown trainee neurologists largely feel unsupported in developing skills in this specialist area.
→ Complete our short survey to help us understand your views as a neurology trainee about pursuing a neurology sub-speciality.
In response to this, we are providing innovative, supportive MasterClass training to enhance trainee’s skills in multiple sclerosis (MS).
This interactive programme, led by national and international experts in MS aims to train a new generation of ‘MSologists’ and will provide graduated training, starting with Basecamp.
Basecamp, through lectures and interactive discussions will help you to develop your skills, Basecamp attendees will also be partnered with a mentor who will offer ongoing support.
The MS Academy Basecamp is the newest of our educational offerings and has been developed to educate trainees earlier in their careers, to cultivate an interest in MS. We hope by exposing trainees to modern MS management earlier, more trainees will be motivated to specialise in MS. Currently the curriculum provides only minimal information on the management of MS; however, by providing a dedicated training and support programme early, we are sure we will be able to generate an increased number of neurologists who want to specialise in MS.
Costs and accommodation:
The course is funded* for UK delegates including accommodation for one night. Delegates are responsible for their own travel costs. Please note, we are unable to accept international delegates for MS Academy Basecamp.
There will be a £100 deposit required to secure your place, this will be invoiced to you upon confirmation. This deposit will be refunded within 30 days of you completing the course. Failure to attend or if you should cancel less than 8 weeks of the course commencement date this will result in the charge of £100.
Places are confirmed on a first come first served basis following receipt of the completed application form. A pre-course needs assessment will need to be completed to ensure the course is adapted for each individual’s needs. This will be sent to you upon confirmation.
→ Please read our terms & conditions.
- Is It Time to Target No Evident Disease Activity (NEDA) in Multiple Sclerosis?
G Giovannoni et al. Mult Scler Relat Disord 4 (4), 329-33. Jul 2015. PMID 26195051. – Review
- Switching Patients at High Risk of PML From Natalizumab to Another Disease-Modifying Therapy
G Giovannoni et al. Pract Neurol 16 (5), 389-93. Oct 2016. PMID 27114560.
- UK Consensus on Pregnancy in Multiple Sclerosis: ‘Association of British Neurologists’ Guidelines
R Dobson et al. Pract Neurol 19 (2), 106-114. Apr 2019. PMID 30612100. – Review
- Disease-modifying Treatments for Early and Advanced Multiple Sclerosis: A New Treatment Paradigm
G Giovannoni. Curr Opin Neurol 31 (3), 233-243. Jun 2018. PMID 29634596. – Review
- Multiple Sclerosis – A Review
R Dobson et al. Eur J Neurol 26 (1), 27-40. Jan 2019. PMID 30300457. – Review
- The Neurodegenerative Prodrome in Multiple Sclerosis
G Giovannoni. Lancet Neurol 16 (6), 413-414. Jun 2017. PMID 28504102.
- Should We Rebrand Multiple Sclerosis a Dementia?
G Giovannoni. Mult Scler Relat Disord 12, 79-81. Feb 2017. PMID 28283112.
*This activity has been supported by sponsorship from Biogen Idec Ltd and Sanofi Genzyme. The sponsors have had no control over the educational content of this activity.